UCL Institute for Innovation and Public Purpose


Health innovation

IIPP will research the ways health innovation can be more mission-oriented to realise major advances in areas of unmet health need, as well as accessibility for patients and populations.

Over the past few decades, huge advances in biomedicine and biotechnology have revolutionised modern medicine. With new treatments, humans have made significant progress in areas that past generation wouldn’t even think possible. In the age of big data and artificial intelligence, innovation is an increasingly important agent for driving transformative societal change as well as economic growth.

Publication highlights

To Browse more IIPP working papers, policy briefs and policy reports, please visit our Publications page.


Rethinking the economics of medical innovation
Rethinking the economics of medical innovation

Learn more

AT2030 project

The AT2030 project is focused on Life Changing Assistive Technology for All, led by the Global Disability and Innovation Hub (GDI Hub) and funded by the UK Department for International Development (DFID). Partners involved in this project include the WHO, Clinton Health Access Initiative (CHAI), UNICEF and other key disability rights groups and innovators.

The aim is to develop a framework in order to best capture and evaluate Assistive Technology (AT) and to better understand return on investment in this sector. The created global evaluation framework will more fully enable a broader understanding of the many spillover effects of the AT supply chain and consequently encourage greater investment into AT.




Further reading


For more information on our work in health innovation policy, please contact Henry Lishi Li, Research Fellow in Health Innovation at IIPP:
Email: henry.li@ucl.ac.uk